ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Fingerprinting the Metabolic and Lipidomic Landscapes of Pancreatic Ductal Adenocarcinoma with MALDI Imaging.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeMetabolic reprogramming plays an integral role in progression, immune evasion, and response to treatment in many cancers, including pancreatic ductal adenocarcinoma (PDAC). This study aimed to spatially characterize the metabolic and lipidomic alterations in PDAC and its precursor lesion, intraductal papillary mucinous neoplasm (IPMN), compared with normal/nonneoplastic pancreatic tissue. EXPERIMENTAL
designMatrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was employed to perform spatial metabolic and lipidomic profiling of human PDAC, IPMN, and normal/nonneoplastic pancreatic tissues. MALDI-MSI provided multiplexed metabolic images of tissue samples at 200 μm resolution, allowing spatial characterization of the tumor metabolic landscape.
resultsOur data identified metabolic signatures characteristic of PDAC, with several of these altered in IPMN compared with normal/nonneoplastic tissue. The metabolic fingerprint of PDAC was characterized by increased levels of taurine, ascorbic acid, and a variety of lipid species, including most of the phosphatidylcholines (PC) and sphingomyelins compared with normal/nonneoplastic pancreas tissue, alongside elevated acetylcarnitine, butyrylcarnitine, and PC (PC 34:3) relative to IPMN; significant reductions were observed in creatine, malate, and lysophosphatidylcholine (LPC 16:0). In contrast, IPMN tissues demonstrated a significant reduction of xanthine, arginine, and tryptophan compared with normal/nonneoplastic pancreas tissue. These metabolic signatures were spatially heterogeneous.
conclusionsOur findings provide novel insights into the metabolic and lipidomic underpinnings of PDAC. Metabolic alterations in PDAC were associated with proliferation, immune evasion, and treatment resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.